Loading...

Purified anti-human CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
29E.2A3 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
29E.2A3_Purified_CD274_Antibody_FC_091013
PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with purified CD274 (clone 29E.2A3) (filled histogram) or purified mouse IgG2b, κ isotype control (open histogram), followed by anti-mouse IgG PE.
  • 29E.2A3_Purified_CD274_Antibody_FC_091013
    PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with purified CD274 (clone 29E.2A3) (filled histogram) or purified mouse IgG2b, κ isotype control (open histogram), followed by anti-mouse IgG PE.
  • 29E.2A3_Purified_CD274_Antibody_IHC-P_112316
    Human paraffin embedded tonsil tissue stained with purified anti-human CD274 (red) antibody. The nuclei were counterstained with DAPI (blue). See additional supplemental data for detailed information.
Compare all formats
Cat # Size Price Quantity Check Availability Save
329701 25 µg $59
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329702 100 µg $83
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full length human PD-L1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-P - Verified
Block - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunohistochemical staining on formalin-fixed paraffin-embedded tissue sections, the suggested use of this reagent is 5.0 - 10 µg per ml. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). 

It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest.

Clone 29E.2A3 does not work in Western blot applications7.

Application References

(PubMed link indicates BioLegend citation)
  1. Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block)
  3. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block)
  4. Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed
  5. Haile, S et al. 2013. J. Immunol. 191:2829.
  6. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed
  7. Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations
  1. Zhou B, et al. 2020. Theranostics. 10:6530. PubMed
  2. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  3. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  4. McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed
  5. Qiao J, et al. 2022. PLoS One. 17:e0277956. PubMed
  6. Niu Q, et al. 2022. Proc Natl Acad Sci U S A. 119:e2213236119. PubMed
  7. Zhang G, et al. 2023. J Immunother Cancer. 11:. PubMed
  8. Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed
  9. Komohara Y, et al. 2018. J Clin Exp Hematop. 58:152. PubMed
  10. Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed
  11. Paterson K, et al. 2022. IEEE Open J Eng Med Biol. 3:86. PubMed
  12. Barsoum I, et al. 2014. Cancer Res. 74:665. PubMed
  13. Hamanishi J, et al. 2015. J Clin Oncol. 101200/JCO2015623397. PubMed
  14. Juttukonda LJ, et al. 2017. Cell Host Microbe. 22:531. PubMed
  15. Heesters BA, et al. 2021. J Exp Med. 218:. PubMed
  16. Hsu DC, et al. 2018. Clin Infect Dis. 67:437. PubMed
  17. Nolan E, et al. 2017. Sci Transl Med. 9:eaal4925. PubMed
  18. Hartley GP, et al. 2018. Cancer Immunol Res. 6:1260. PubMed
  19. Lee SWL, et al. 2018. Front Immunol. 8:1064. PubMed
  20. Zeller AN, et al. 2021. Eur Cell Mater. 41:603. PubMed
  21. Agrawal N, et al. 2018. Front Immunol. 2.053472222. PubMed
  22. Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed
  23. Li C, et al. 2016. Nat Commun. 7:12632. PubMed
  24. Kim DH, et al. 2019. Exp Mol Med. 51:94. PubMed
  25. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  26. Baruah P, et al. 2019. Front Immunol. 10:1644. PubMed
  27. Salvany‐Celades M et al. 2019. Cell Rep. 27(9):2537-2547 . PubMed
  28. Acheampong E, et al. 2019. Cancers (Basel). 11. PubMed
  29. Schwabenland M, et al. 2021. Immunity. . PubMed
  30. Saber MM, et al. 2022. Antibodies (Basel). 11:. PubMed
  31. Hang Q, et al. 2020. Zhongguo Fei Ai Za Zhi. 1.539583333. PubMed
  32. Kim MH, et al. 2018. Cancer Immunol Res. 0.427083333. PubMed
  33. Kennedy-Darling J, et al. 2021. Eur J Immunol. 51:1262. PubMed
  34. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  35. Wang Y, et al. 2019. Sci Rep. 9:566. PubMed
  36. Burr ML, et al. 2017. Nature. 549:101. PubMed
  37. Janse van Rensburg HJ, et al. 2018. Cancer Res. 78:1457. PubMed
  38. Enyindah-Asonye G, et al. 2019. Front Immunol. 10:511. PubMed
  39. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  40. Hwang HJ, et al. 2021. Immun Inflamm Dis. 9:274. PubMed
  41. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
RRID
AB_940370 (BioLegend Cat. No. 329701)
AB_940370 (BioLegend Cat. No. 329702)

Antigen Details

Distribution

T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells

Function
CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.

Gene ID
29126 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD274 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC-P,Block
Biotin anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
PE anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
APC anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 421™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Ultra-LEAF™ Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC,Block
PE/Cyanine7 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar® Ready) 29E.2A3 FC,CyTOF®
Brilliant Violet 711™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 605™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
GoInVivo™ Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC,IHC,Block
PE/Dazzle™ 594 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 510™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
PerCP/Cyanine5.5 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 650™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Alexa Fluor® 594 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 IHC-P
TotalSeq™-A0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-B0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-C0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-D0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
PE/Fire™ 810 anti-human CD274 (B7-H1, PD-L1) Antibody 29E.2A3 FC
PE/Cyanine5 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Spark YG™ 570 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 IHC-P,FC
Go To Top Version: 10    Revision Date: 08/16/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account